Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07807059 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Sep 2026 to Sep 9, 2026 · Site details revised Show 2 more changesShow less
    • Start date changed from estimate of Sep 2026 to Sep 9, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Fujian Shengdi Pharmaceutical Co., Ltd.
43 trials monitored
See 3 trials at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
Type 2 Diabetes
2,100 trials monitored
See 102 trials at risk
and 1 more disease
This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8 healthy participants.
Trial Details
NCT Number NCT07807059
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov